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INTRODUCTION
Implantable cardioverter-defibrillators (ICDs) are effective in 
improving survival in patients who have experienced sudden 
cardiac arrest.1-4 Previous large-scale randomized trials have 
shown that ICDs are also beneficial in patients at high risk who 
have not experienced sudden cardiac arrest, such as selective 
patients with heart failure (HF) with reduced ejection fraction.5-9 
According to the 2013 American College of Cardiology Founda-
tion/American Heart Association guidelines for the manage-
ment of HF, ICD implantation is recommended for primary pre-
vention of sudden cardiac death in patients with HF with an 
ejection fraction ≤35% and New York Heart Association (NYHA) 
functional class II or III on optimal medical therapy, based on 
Class of Recommendation (I) and Level of Evidence (A).10 The 
MADIT-RIT trial showed that inappropriate ICD therapy and 
all-cause mortality can be reduced by programming a high-rate 
ICD therapy zone.11 However, inappropriate and unnecessary 
ICD therapies remain challenging problems. In addition, the 
complication rate related to ICD implantation is not negligible.12 
The long-term prognosis of Asian patients with HF and ICD for 
primary prevention is not well-known. The purpose of this study 
was to elucidate annual ICD therapy rates and the effects of a 
high-rate ICD therapy zone in Korean patients with ICD.
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MATERIALS AND METHODS
The study design was approved by an Institutional Review 
Board and was conducted in compliance with the Declaration 
of Helsinki. We consecutively enrolled 405 patients (age, 57.7± 
16.7 years; 311 men) who underwent ICD or cardiac resynchro-
nization therapy-defibrillator (CRT-D) implantation between 
October 1997 and March 2015 in the Severance ICD and CRT 
registry. The patients were divided into three groups: HF with 
ICD or CRT-D for primary (group 1) and secondary prevention 
(group 2) and non-HF with ICD for primary and secondary 
prevention (group 3). ICDs and CRT-Ds were implanted ac-
cording to the contemporary guidelines for ICD and CRT-D 
implantation.13-15 Patients with an ICD or CRT-D were seen for 
follow-up at the outpatient clinic every 3 months or on special 
occasions, including ICD alarm and ICD therapy delivery. We 
reviewed medical records to obtain information on baseline 
clinical characteristics, electrocardiography, cardiac imaging 
studies (including echocardiography, computed tomography, 
and magnetic resonance images), coronary angiography, clini-
cal diagnoses, ICD indications, defibrillator types, appropriate 
and inappropriate ICD therapy, and mortality. HF was defined 
as a left ventricular ejection fraction ≤40% and included non-
ischemic (including dilated cardiomyopathy) and ischemic HF. 
Non-HF heart disease included inherited primary arrhythmia 
syndrome (Brugada syndrome, long QT syndrome, early repo-
larization syndrome, catecholaminergic polymorphic ventric-
ular tachycardia, and idiopathic ventricular fibrillation); hy-
pertrophic, restrictive, and arrhythmogenic right ventricular 
cardiomyopathies; and congenital heart disease. ICD indica-
tions were classified as primary and secondary prevention of 
sudden cardiac death. Secondary prevention was defined as 
prevention in patients who had experienced sudden cardiac ar-
rest or sustained ventricular tachyarrhythmia. In contrast, pri-
mary prevention was defined as prevention in patients who 
had not previously experienced sudden cardiac arrest or sus-
tained ventricular tachyarrhythmia. Defibrillator types in-
cluded single- and dual-chamber ICDs and CRT-D. High- and 
low-rate ICD therapy zones, defined according to the heart rate 
that triggers ICD therapy, were set at ≥200 /min and <200 /min, 
respectively. A high-rate ICD therapy zone was set according to 
the physicians’ discretion. Appropriate ICD therapy was de-
Table 1. Baseline Characteristics of the Patients in Each Group
Group 1 (n=118) Group 2 (n=93) Group 3 (n=194) p value
Age (yr) 65.5±12.2 64.6±13.4 49.7±16.8 <0.001*
Male, n (%) 79 (66.9) 70 (75.3) 162 (83.5) 0.003†
Hypertension, n (%) 52 (44.1) 47 (50.5) 41 (21.1) <0.001*
Diabetes, n (%) 47 (39.8) 27 (29.0) 15 (7.7) <0.001*
Atrial fibrillation, n (%) 41 (34.7) 18 (19.4) 11 (5.7) <0.001*
NYHA functional class 2.5±0.6 2.0±0.9 <0.001
Ejection fraction (%) 23.6±6.6 33.2±12.3 61.7±11.3 <0.001‡
Etiology, n (%)
Non-ischemic HF 78 (66.1) 45 (48.4) 0.010
Ischemic HF 40 (33.9) 48 (51.6) 0.010
IPAS 127 (65.5)
HCMP 37 (19.1)
ARVC 13 (6.7)
CHD 12 (6.2)
RCMP 3 (1.5)
Miscellanea 2 (1.0)
β-blocker use, n (%) 81 (68.6) 72 (77.4) 150 (77.3) 0.187
Amiodarone use, n (%) 21 (17.8) 36 (38.7) 13 (6.7) <0.001‡
ACEI/ARB use, n (%) 105 (89.0) 78 (83.9) 31 (16.0) <0.001*
Defibrillator type, n (%)
Single-chamber 37 (31.4) 60 (64.5) 141 (72.7) <0.001‡
Dual-chamber 42 (35.6) 29 (31.2) 53 (27.3) 0.257
CRT-D 39 (33.1) 4 (4.3) 0 (0.0) <0.001
High-rate ICD therapy zone, n (%) 56 (47.5) 45 (48.4) 129 (66.5) 0.001†
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARVC, arrhythmogenic right ventricular cardiomyopathy; CHD, congenital 
heart disease; CRT-D, cardiac resynchronization therapy-defibrillator; HCMP, hypertrophic cardiomyopathy; HF, heart failure; ICD, implantable cardioverter-defi-
brillator; IPAS, inherited primary arrhythmia syndrome; NYHA, New York Heart Association; RCMP, restrictive cardiomyopathy.
*Group 3 is significantly different from groups 1 and 2, †Group 3 is significantly different from groups 1, ‡The three groups are significantly different from each 
other.
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fined as anti-tachycardial pacing and ICD shock for ventricu-
lar tachyarrhythmia. In contrast, inappropriate ICD therapy 
was defined as anti-tachycardial pacing and ICD shock for ar-
rhythmias other than ventricular tachyarrhythmia. Outcomes 
included appropriate and inappropriate ICD therapy delivery 
and all-cause mortality. We compared the annual numbers of 
patients who experienced appropriate and inappropriate ICD 
therapy and mortality among the patients in the three groups. 
We also analyzed the annual numbers of patients who experi-
enced appropriate and inappropriate ICD therapy and mor-
tality between patients with high- and low-rate ICD therapy 
zones in each group.
Statistical analyses 
The results are expressed as means±standard deviations for 
continuous data and numbers (%) for categorical data. We 
compared clinical parameters among the groups using Stu-
dent’s t-test or ANOVA for normally distributed continuous 
data and the χ2 test for categorical data. The Kaplan-Meier 
method was used to analyze cumulative incidence rates for ap-
propriate and inappropriate ICD therapy and mortality. Appro-
priate and inappropriate ICD therapy and all-cause mortality 
among the groups were compared by log-rank test. A p value 
<0.05 was considered significant. Data were analyzed using the 
Statistical Package for the Social Sciences, version 20.0 (IBM 
Corporation, Armonk, NY, USA).
RESULTS
Baseline characteristics and appropriate/inappropriate 
ICD therapy in each group
Table 1 shows the baseline characteristics of all 405 patients 
stratified by group, including 118 patients in group 1, 93 pa-
tients in group 2, and 194 patients in group 3. The diagnoses 
of patients in group 3 were as follows: idiopathic ventricular 
fibrillation in 60 patients, Brugada syndrome in 47 patients, 
long QT syndrome in 13 patients, early repolarization syndrome 
in 6 patients, and catecholaminergic polymorphic ventricular 
tachycardia in 1 patient. The patients were followed for 58.9± 
49.8 months. The patients in group 1 had a significantly higher 
NYHA functional class, lower ejection fraction, higher frequen-
cy of non-ischemic HF, and fewer single-chamber ICDs than 
the patients in group 2. The patients in group 1 were signifi-
cantly older, more often female, had higher frequencies of hy-
pertension, diabetes mellitus, atrial fibrillation, a lower ejection 
fraction, fewer single-chamber ICDs, and less frequent high-
rate ICD therapy zone than the patients in group 3. Significantly 
Table 2. Outcomes of the Patients in Each Group
Group 1 (n=118) Group 2 (n=93) Group 3 (n=194) p value
Follow-up period (months) 31.7±33.5 61.8±42.7 73.9±54.4 <0.001*
Patients who experienced appropriate ICD therapy, annual (%) 6.1 10.4 5.9 <0.001†
Patients who experienced inappropriate ICD therapy, annual (%) 3.2 4.2 3.2 0.171
Annual mortality (%) 4.5 3.8 0.4 <0.001‡
ICD, implantable cardioverter-defibrillator.
*The three groups are significantly different from each other, †Group 2 is significantly different from groups 1 and 3, ‡Group 3 is significantly different from 
groups 1 and 2.
Fig. 1. Appropriate (A) and inappropriate (B) implantable cardioverter-defibrillator (ICD) therapy, and all-cause mortality (C) in patients in three groups. 
Group 1, heart failure (HF) and ICD for primary prevention; group 2, HF and ICD for secondary prevention; group 3, non-HF and ICD. 
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more patients in group 2 experienced appropriate ICD therapy 
per year than the patients in group 1 (Table 2, Fig. 1A). How-
ever, there were no significant differences in annual inappro-
priate ICD therapy and annual mortality between groups 1 
and 2 (Table 2, Fig. 1B). There were no significant differences 
in the annual number of patients who received appropriate 
and inappropriate ICD therapy between groups 1 and 3 (p= 
0.309 and 0.126, respectively) (Fig. 1). However, annual mor-
tality was significantly higher in groups 1 and 2 than in group 
3 (Table 2, Fig. 1C). Ten (8.5%), 20 (21.5%), and 39 (20.1%) pa-
tients experienced inappropriate ICD therapy in groups 1, 2, 
and 3, respectively. In groups 1 and 2, the causes of inappro-
priate ICD therapy were atrial fibrillation (14 patients), noise 
sensing (8 patients), T wave oversensing (3 patients), sinus 
tachycardia (3 patients), and supraventricular tachycardia (2 
patients). In group 3, the causes of inappropriate ICD therapy 
were sinus tachycardia (11 patients), atrial fibrillation (8 pa-
tients), noise sensing (7 patients), supraventricular tachycardia 
(6 patients), T wave oversensing (4 patients), and unknown 
cause (3 patients). 
High- and low-rate ICD therapy zones (Table 3)
Among patients in group 1, 56 patients (47.5%) had a high-
rate ICD therapy zone. Hypertension was significantly more 
frequent among patients with a high-rate ICD therapy zone 
than a low-rate ICD therapy zone. Patients with a high-rate ICD 
therapy zone experienced appropriate ICD therapy signifi-
cantly less frequently than patients with a low-rate ICD therapy 
zone, when assessed annually (3.7% and 10.6%, respectively, 
p=0.026) (Fig. 2A). There were no significant differences in an-
nual numbers of patients who experienced inappropriate ICD 
therapy between patients with a high- or low-rate ICD therapy 
zone (1.9% and 5.7%, respectively, p=0.404) (Fig. 3A). There 
were also no significant differences in annual mortality be-
tween the patients with a high- or low-rate ICD therapy zone 
(5.0% and 4.0%, respectively, p=0.487). 
Among patients in group 2, 45 patients (48.4%) had a high-
rate ICD therapy zone. There was no significant difference in 
the baseline characteristics between patients of a high- and 
low-rate ICD therapy zone. There were no significant differenc-
es in the annual numbers of patients who experienced appro-
priate ICD therapy between the patients with a high- or low-
rate ICD therapy zone (9.3% and 11.5%, respectively, p=0.277) 
(Fig. 2B). There were no significant differences in the annual 
numbers of patients who experienced inappropriate ICD ther-
apy between the patients with a high- or low-rate ICD therapy 
zone (4.3% and 4.1%, respectively, p=0.893) (Fig. 3B).
Among patients in group 3, 129 patients (66.5%) had a high-
rate ICD therapy zone. Dual-chamber ICD was significantly 
more frequent in patients of a low-rate ICD therapy zone than 
a high-rate ICD therapy zone. Patients with a high-rate ICD 
therapy zone experienced inappropriate ICD therapy signifi-
cantly less frequently than patients with a low-rate ICD thera-
py zone, when assessed annually (2.7% and 5.7%, respectively, 
p=0.048) (Fig. 3C). There were no significant differences in the 
annual numbers of patients who experienced appropriate ICD 
therapy between the patients with a high- or low-rate ICD ther-
apy zone (5.5% and 8.8%, respectively, p=0.200) (Fig. 2C). There 
were also no significant differences in annual mortality between 
patients with a high- or low-rate ICD therapy zone (0.3% and 
Table 3. Baseline Characteristics and Outcomes in the Patients of a High- and Low-Rate ICD Therapy Zone in Each Group
Group 1 Group 2 Group 3
High-rate
(n=56)*
Low-rate
(n=60)*
High-rate
(n=45)*
Low-rate
(n=47)*
High-rate
(n=129)*
Low-rate
(n=64)*
Age (yr) 66.2±13.0 64.8±11.7 61.8±13.4 67.1±13.2 49.3±16.2 50.1±17.9
Male, n (%) 40 (71.4) 37 (61.7) 33 (73.3) 37 (78.7) 105 (81.4) 57 (89.1)
Hypertension, n (%) 31 (55.4)† 20 (33.3)† 21 (46.7) 25 (53.2) 25 (19.4) 16 (25.0)
Diabetes, n (%) 27 (48.2) 19 (31.7) 14 (31.1) 13 (27.7) 7 (5.4) 8 (12.5)
Ischemic HF, n (%) 24 (42.9) 16 (26.7) 21 (46.7) 26 (55.3) 0 (0) 0 (0)
NYHA functional class 2.5±0.6 2.6±0.5 1.9±0.9 2.1±0.9 − −
Ejection fraction (%) 23.8±8.3 23.4±4.5 33.5±12.1 33.0±12.7 63.5±10.4† 58.3±12.2†
Defibrillator type, n (%)
Single-chamber 21 (37.5) 14 (23.3) 32 (71.1) 28 (59.6) 101 (78.3)† 39 (60.9)†
Dual-chamber 34 (60.7) 45 (75.0) 11 (24.4) 18 (38.3) 28 (21.7)† 25 (39.1)†
CRT-D 1 (1.8) 1 (1.7) 2 (4.4) 1 (2.1) 0 (0) 0 (0)
Follow-up period (month) 34.3±30.7 24.6±23.7 68.5±46.4 55.4±38.8 83.9±53.3† 51.9±48.1†
Patients who experienced ICD therapy (%)
Appropriate, annual 3.7† 10.6† 9.3 11.5 5.3 8.3
Inappropriate, annual 1.9 5.7 4.3 4.1 2.7† 5.4†
Annual mortality 5.0 4.0 1.9 6.0 0.4 0.4
CRT-D, cardiac resynchronization therapy-defibrillator; HF, heart failure; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association.
*ICD therapy zone has been changed in 2, 1, and 1 patient in group 1, 2, and 3, respectively, †p<0.05.
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0.4%, respectively, p=0.227).
DISCUSSION
This was a cohort study using real-world ICD registry data. The 
main findings of the present study are that 1) the annual propor-
tions of the patients in groups 1, 2, and 3 who experienced ap-
propriate ICD therapy were 6.1, 10.4, and 5.9%, respectively; 2) 
for patients in group 1, the annual appropriate ICD therapy rate 
was significantly lower in patients with a high-rate ICD therapy 
zone than in patients with a low-rate ICD therapy zone; and 3) 
for patients in group 3, the annual inappropriate ICD therapy 
rate was significantly lower in patients with a high-rate ICD 
therapy zone than in patients with a low-rate ICD therapy zone. 
Previous prospective randomized trials and real-
world registry data on ICDs for primary prevention 
of sudden cardiac death 
Many previous large-scale prospective randomized trials have 
shown that survival benefits can be obtained by ICD use in pa-
tients with HF and a reduced ejection fraction. In the previous 
studies evaluating the use of ICDs for primary prevention of 
sudden cardiac death, the following annual appropriate ICD 
therapy rates have been reported and are presented in the or-
der of publication date: 17% in the MADIT-II trial,16 7.4% in 
the DEFINITE trial,8 5.1% in the SCD-HeFT trial,9 5.4% in the 
PREPARE study,17 and 5.2% in the MADIT-RIT trial.11 The an-
nual inappropriate ICD therapy rates were as follows: 8.9% in 
the DEFINITE trial,8 2.4% in the SCD-HeFT trial,9 3.1% in the 
PREPARE study,17 and 3.4% in the MADIT-RIT trial.11 Previous 
real-world registry data have included appropriate and inap-
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Fig. 2. Appropriate implantable cardioverter-defibrillator (ICD) therapy according to ICD therapy zones (high-rate ICD therapy zone vs. low-rate ICD 
therapy zone) in group 1 (A), 2 (B), and 3 (C). Group 1, heart failure (HF) and ICD for primary prevention; group 2, HF and ICD for secondary prevention; 
group 3, non-HF and ICD.
Fig. 3. Inappropriate implantable cardioverter-defibrillator (ICD) therapy according to ICD therapy zones (high-rate ICD therapy zone vs. low-rate ICD 
therapy zone) in group 1 (A), 2 (B), and 3 (C). Group 1, heart failure (HF) and ICD for primary prevention; group 2, HF and ICD for secondary prevention; 
group 3, non-HF and ICD.
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propriate ICD therapy rates in patients with ICD for primary 
prevention. Swedish registry data indicated annual appropri-
ate and inappropriate ICD therapy rates of 6.0% and 2.4% in 
865 patients with an ICD for primary prevention, respective-
ly.18 Israeli registry data revealed that annual appropriate ICD 
therapy rates were 3.9% and 8.4% and that annual inappropri-
ate ICD therapy rates were 2.0% and 1.8% in 1766 and 583 pa-
tients with an ICD for primary or secondary prevention, respec-
tively.19 Appropriate and inappropriate ICD therapy rates tend 
to decrease over time. This may be because unnecessary ICD 
therapy can be avoided using a high-rate ICD therapy zone and 
delayed detection time. There is a paucity of real-world ICD 
registry data for Asian patients with HF. According to Japanese 
registry data on patients with chronic HF, fatal arrhythmic 
events occurred in 16.1% and 8.9% of patients who met class I 
and IIa indications for ICD implantation, respectively.20 A retro-
spective study on Korean patients with HF reported a sudden 
cardiac death rate of 8% during 40 months of follow-up in pa-
tients who met the ICD indications for primary prevention.21 In 
the present study, the annual appropriate and inappropriate 
ICD therapy rates in patients with HF using an ICD for primary 
prevention are comparable with those of the recent prospective 
randomized trials and real-world registry data.
High- and low-rate ICD therapy zones
In patients with HF and ICD for primary prevention, high ap-
propriate and inappropriate ICD shock rates have been associ-
ated with a high risk of mortality.22 The PainFREE Rx II trial 
showed that anti-tachycardial pacing was effective for reducing 
appropriate ICD shock for fast ventricular tachycardia.23 The 
MADIT-RIT and ADVANCE III trials showed that a high-rate 
ICD therapy zone and long-detection interval could reduce in-
appropriate and unnecessary ICD shocks.11,24 In the present 
study, a high-rate ICD therapy zone was associated with a low 
appropriate ICD therapy rate in patients with HF and ICD for 
primary prevention. However, a high-rate ICD therapy zone was 
not associated with inappropriate ICD therapy rate or mortality 
in these patients. Although we could not completely differenti-
ate necessary ICD therapy from unnecessary ICD therapy in ap-
propriate ICD therapy, the present results suggest that a high-
rate ICD therapy zone could reduce unnecessary ICD therapy in 
patients with HF and ICD for primary prevention. In our analy-
sis, it was difficult to say whether the ventricular tachyarrhyth-
mia treated by ICD therapy would have been fatal without ICD.
In the present study, a high-rate ICD therapy zone was as-
sociated with a low inappropriate ICD therapy rate in the non-
HF patients. Since the patients in group 3 were younger than 
the patients with groups 1 and 2, they could have higher phys-
ical activity. Therefore, there may be a high probability of in-
appropriate ICD therapy for sinus tachycardia in non-HF pa-
tients. In this study, the most common cause of inappropriate 
ICD therapy was also sinus tachycardia in group 3. The present 
results suggest that a high-rate ICD therapy zone might re-
duce inappropriate ICD therapy for sinus tachycardia in non-
HF patients with ICD. 
It is not clear why a high-rate ICD therapy zone did not re-
duce ICD therapy delivery in the patients in groups 2. We spec-
ulate that unnecessary ICD therapies for non-sustained ven-
tricular tachyarrhythmia did not occur frequently in patients 
with HF and ICD for secondary prevention.
Inappropriate ICD therapy
The common causes of inappropriate ICD shock are atrial fi-
brillation, supraventricular tachycardia, and abnormal sensing 
in patients with prior myocardial infarction who are using an 
ICD for primary prevention.25 In Korean patients, atrial fibrilla-
tion is a predictor of inappropriate shock.26 In the present study, 
the most common cause of inappropriate ICD therapy in pa-
tients with HF was atrial fibrillation. However, in non-HF pa-
tients, the most common cause of inappropriate ICD therapy 
was sinus tachycardia. Age and underlying heart disease could 
contribute to the difference in the main causes of inappropriate 
ICD therapy. Higher incidence of atrial fibrillation occurred in 
patients with HF due to older age and reduced ejection frac-
tion. In contrast, high physical activity levels and high incidence 
of sinus tachycardia were more likely in non-HF patients as 
they were younger and had a preserved ejection fraction. Due 
to high numbers of oversensing issues, management of ICD 
hardware and meticulous ICD programming are necessary to 
reduce inappropriate ICD therapy.
Study limitations
This was a cohort study based on real-world registry data rath-
er than a prospective randomized trial. It was difficult to differ-
entiate between necessary and unnecessary ICD therapy in 
the patients who experienced appropriate ICD therapy. Addi-
tionally, data about the arrhythmia detection interval of the 
ICDs were not available in all patients. Large-scale prospective 
randomized trials in Asian patients are necessary. 
In conclusion, appropriate ICD therapy rates are not low in 
Korean patients with ICD, relative to prior large-scale studies in 
Western countries. Appropriate and inappropriate ICD therapy 
could be reduced by a high-rate therapy zone in patients with 
HF and ICD for primary prevention and non-HF patients, re-
spectively.
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